文献速递乳腺癌妇科肿瘤胸部肿瘤

PARP抑制剂他拉唑帕利在晚期胚系BRCA1/2突变及部分散发性癌症患者中的I期剂量递增两部分试验

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
PubMed 文献 · Cancer Discov · 2017-02-27

这项两部分、I期、首次人体试验评估了他拉唑帕利在晚期胚系BRCA1/2突变及部分散发性癌症患者中的抗肿瘤活性、最大耐受剂量、药代动力学和药效动力学。最大耐受剂量为1.0 mg/天,消除半衰期为50小时;在1.0 mg/天剂量下,BRCA突变相关乳腺癌和卵巢癌患者的确认缓解率分别为7/14(50%)和5/12(42%),胰腺癌和小细胞肺癌患者中也观察到缓解。他拉唑帕利显示出单药抗肿瘤活性且耐受性良好。

要点

  • 最大耐受剂量为1.0 mg/天,消除半衰期为50小时。
  • 治疗相关不良事件包括疲乏(26/71例;37%)和贫血(25/71例;35%)。
  • 1.0 mg/天剂量下,BRCA突变相关乳腺癌确认缓解7/14(50%),卵巢癌5/12(42%)。

核心结论

  • 他拉唑帕利在推荐剂量1.0 mg/天下显示出单药抗肿瘤活性且耐受性良好。

研究设计与样本

  • 这项两部分、I期、首次人体、开放标签、多中心、剂量递增试验(NCT01286987)评估了每日一次他拉唑帕利的抗肿瘤活性、最大耐受剂量、药代动力学和药效动力学。
  • 共71例患者报告了治疗相关不良事件。

主要发现

  • 最大耐受剂量为1.0 mg/天,消除半衰期为50小时。
  • 治疗相关不良事件包括疲乏(26/71例;37%)和贫血(25/71例;35%)。
  • 3至4级不良事件包括贫血(17/71例;24%)和血小板减少(13/71例;18%)。
  • 在剂量≥0.60 mg/天时观察到持续性PARP抑制。
  • 在1.0 mg/天剂量下,BRCA突变相关乳腺癌患者中确认缓解7/14(50%),BRCA突变相关卵巢癌患者中确认缓解5/12(42%),胰腺癌和小细胞肺癌患者中也观察到缓解。

关键数值与推荐

  • 最大耐受剂量为1.0 mg/天。
  • 消除半衰期为50小时。
  • 在剂量≥0.60 mg/天时观察到持续性PARP抑制。
  • 1.0 mg/天剂量下,BRCA突变相关乳腺癌确认缓解7/14(50%),BRCA突变相关卵巢癌确认缓解5/12(42%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Talazoparib inhibits PARP catalytic activity, trapping PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We evaluated talazoparib therapy in this two-part, phase I, first-in-human trial. Antitumor activity, MTD, pharmacokinetics, and pharmacodynamics of once-daily talazoparib were determined in an open-label, multicenter, dose-escalation study (NCT01286987). The MTD was 1.0 mg/day, with an elimination half-life of 50 hours. Treatment-related adverse events included fatigue (26/71 patients; 37%) and anemia (25/71 patients; 35%). Grade 3 to 4 adverse events included anemia (17/71 patients; 24%) and thrombocytopenia (13/71 patients; 18%). Sustained PARP inhibition was observed at doses ≥0.60 mg/day. At 1.0 mg/day, confirmed responses were observed in 7 of 14 (50%) and 5 of 12 (42%) patients with BRCA mutation-associated breast and ovarian cancers, respectively, and in patients with pancreatic and small cell lung cancer. Talazoparib demonstrated single-agent antitumor activity and was well tolerated in patients at the recommended dose of 1.0 mg/day.Significance: In this clinical trial, we show that talazoparib has single-agent antitumor activity and a tolerable safety profile. At its recommended phase II dose of 1.0 mg/day, confirmed responses were observed in patients with BRCA mutation-associated breast and ovarian cancers and in patients with pancreatic and small cell lung cancer. Cancer Discov; 7(6); 620-9. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 539.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. de Bono J, Ramanathan RK, Mina L, et al. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017. PMID: 28242752. doi:10.1158/2159-8290.CD-16-1250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。